US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    ExpreS2ion to present in upcoming investor and scientific events

    Hørsholm, Denmark, 31 October2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including BIO-Europe, the Protein & Antibody Engineering Summit Europe, a 2024 Third Quarter Results Webinar, and the LSX Investival Showcase.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website 

    The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split

    Hørsholm, Denmark, 24 October 2024 - At the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") on 21 October 2024, it was resolved on a reverse share split of the Company's shares, whereby forty (40) existing shares shall be consolidated into one (1) share (Sw. sammanläggning 1:40). The Board of Directors was authorized by the Extraordinary General Meeting to determine the record date for the reverse share split. The Board of Directors has today resolved that the record date for the reverse share split shall be 31 October 2024. Due to the

    Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)

    Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the "EGM"). Notice of the EGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.Resolution on a directed issue of shares (equalization issue)The EGM resolved, in accordance with the Board of Directors' proposal, on an issue of not more than 384,530 new shares with deviation from the shareholders' preferential rights. Through the share issue, the Company's share capital will

    ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines

    Hørsholm, Denmark, 16 October 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, announces that a term sheet has been entered with Serum Institute of India Private Limited (“SIIPL”), the world’s largest vaccine manufacturer. Upon execution of a definitive agreement on terms to be mutually agreed, SIIPL will obtain exclusive licensing rights to develop, manufacture, and commercialise certain malaria vaccine product lines,

    Notice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

    N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on 21 October 2024 at 10.00 (CEST) on Mindpark, Bredgatan 11, Helsingborg, Sweden. The entrance to the meeting and registration will commence at 09.30 (CEST).The Board of Directors have decided, pursuant to the Company’s articles of association,

    ExpreS2ion to present in upcoming investor events

    Hørsholm, Denmark, 10 September 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events, including Investing in Life Science: From Seed to Success and a Danish Stock seminar for institutional investors.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below. 12 September 2024 |

    ExpreS2ion announces publication of sponsored research reports

    Hørsholm, Denmark, 23 August 2024 – ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2) is pleased to announce the publication of two new research reports by sponsored analysts, which delve into the fundamentals of the company’s innovative pipeline and proprietary ExpreS2 platform.The reports, authored by Analysguiden and Pareto Securities, provide detailed analyses of ExpreS2ion’s lead asset, ES2B-C001, and the broader development pipeline. Key Highlights: · Analysguiden Report: Titled “At the Gates of Phase I,” this report emphasizes the outlook for ES2B-C001

    ExpreS2ion announces financial results for the second quarter of 2024

    Hørsholm, Denmark, 15 August 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter and half-year financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments:“On the first of July, we announced the completion of a rights issue raising gross proceeds of SEK 30 million. With a cash position of SEK 68.6 million at the end of the second quarter, ExpreS2ion is funded to initiate the ES2B-C001 first-in-human Phase I trial, subject to

    ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine

    Hørsholm, Denmark, 06 August 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, is proud to announce the submission of ExpreS2ion’s first CTA, to the Austrian Agency for Health and Food Safety (BASG/AGES) for its novel therapeutic candidate, ES2B-C001 against breast cancer. This submission marks an important milestone in the company’s objective to address significant unmet medical needs in oncology.ES2B-C001 is a first-

    ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. Hørsholm, Denmark, 5 July 2024 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ)  ("ExpreS2ion" or the "Company") has today, on 5 July 2024, based on the

    ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens

    Hørsholm, Denmark, 3 July 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") a late preclinical stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for the patent "Glyco-Engineered Immunization Antigens”. Granting of the patent in the U.S. validates the patentability of ExpreS2ion’s technology platform patent portfolio, thus representing a significant value inflection point

    ExpreS2ion announces final outcome of its rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. Hørsholm, Denmark, 1 July 2024 – ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has completed the issue of a maximum of 59,972,451 units, consisting

    Rights issue subscription period ending 27 June 2024; subscription possible via form

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. Hørsholm, Denmark, 26 June 2024 – Tomorrow, 27 June 2024, is the last day of the subscription period in ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “

    ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting

    Hørsholm, Denmark, 24 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company presented a poster on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens, at the European Society for Animal Cell Technology (ESACT) bi-annual meeting, taking place 23-26 June 2024, in Edinburgh, Scotland.The presentation poster titled “Use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens” showcases novel glyco-modified versions of the ExpreS2 platform (GlycoX-

    Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

    Hørsholm, Denmark, 21 June 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet of a scientific paper titled “Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial”. The article is based on a clinical study conducted by researchers at the University of Oxford.Chief Scientific Officer Farshad Guirakhoo comments: “These are the first data on the RH5.1/Matrix-M blood-stage malaria

    ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine

    Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces that its recent webinar covering the 2024 rights issue, hosted by CEO Bent Frandsen and CFO Keith Alexander, is now available for on-demand viewing. The webinar  provided insights into the background and rationale for the rights issue, detailed the intended use of proceeds, outlined the structure of the offering, and explained how to participate. Additionally, CEO Bent Frandsen has recently delivered significant presentations at

    BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I

    Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK 60 million rights issue of units will fund a phase I study with the breast cancer vaccine candidate ES2B-C001, building on promising preclinical results. The capital raise will also support the cytomegalovirus vaccine discovery project in the Evaxion collaboration, and other working capital including in the grant sponsored research and development.Read the full article at biostock.se : https://www.biostock.se/2024/06/rights-issue-takes-

    ExpreS2ion CEO to BioStock: “Compelling preclinical package gives us confidence”

    Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies. A SEK 60 million rights issue is underway to fund this pivotal step. CEO Bent U. Frandsen discussed the current development and the future plans ahead with BioStock.Read the full article at biostock.se : https://www.biostock.se/2024/06/expres2ion-ceo-compelling-preclinical-package-gives-us-confidence/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    The subscription period in ExpreS2ion’s rights issue begins today

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. Hørsholm, Denmark, 12 June 2024 – Today is the first day of the subscription period in ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “Company”) rights

    ExpreS2ion to present in upcoming investor and scientific events

    Hørsholm, Denmark, 10 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including a webcast about the 2024 Rights Issue and the 2024 European Society for Animal Cell Technology (ESACT) meeting.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website 

    ExpreS2ion publishes prospectus in connection with its rights issue of units

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW. Hørsholm, Denmark, 5 June 2024 – On 2 May 2024, the Board of Directors of ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) resolved, conditional upon

    Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024

    The Annual General Meeting 2024 (the "AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 5 June 2024.Adoption of the income statement and the balance sheet The AGM resolved to adopt the income statement and balance sheet and the group income statement and group balance sheet as presented in the annual report for the financial year 2023. Allocation of profit The AGM resolved, in accordance with the board's proposal, that all funds available to the AGM shall be carried forward. Discharge from liability The Board of Directors and the CEO

    ExpreS2ion announces financial results for the first quarter of 2024

    Hørsholm, Denmark, 16 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “We are starting 2024 invigorated by our new strategy with clear objectives, the strong progress of our proprietary pipeline, and a broadly validated platform. The overall conditions for early-stage biotech funding remain challenging and selective. Against this backdrop, we have established our

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media